These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 22309333)
1. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Foster RS; Bint LJ; Halbert AR Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333 [TBL] [Abstract][Full Text] [Related]
2. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960 [TBL] [Abstract][Full Text] [Related]
3. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052 [TBL] [Abstract][Full Text] [Related]
4. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis. Mutizwa MM; Berk DR; Anadkat MJ Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776 [No Abstract] [Full Text] [Related]
5. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. Kaufman McNamara E; Curtis AR; Fleischer AB J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154 [TBL] [Abstract][Full Text] [Related]
6. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions. Tu J; Foster RS; Bint LJ; Halbert AR Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523 [TBL] [Abstract][Full Text] [Related]
7. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771 [TBL] [Abstract][Full Text] [Related]
8. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683 [TBL] [Abstract][Full Text] [Related]
9. Targeted topical and combination laser surgery for the treatment of angiofibromas. Bae-Harboe YS; Geronemus RG Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial. Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201 [TBL] [Abstract][Full Text] [Related]
11. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. Wheless JW; Almoazen H J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial. Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H; JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048 [TBL] [Abstract][Full Text] [Related]
13. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus]. Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155 [TBL] [Abstract][Full Text] [Related]
14. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel. Krakowski AC; Nguyen TA Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829 [TBL] [Abstract][Full Text] [Related]